Renvistobart
As of the edition of 20 October 2026, Renvistobart is an antibody: stopped in 2024; acts on TIGIT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 4, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Heart and blood vessels; Hormones; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Renvistobart.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains | Q495A1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 4 | 3 | 0 | 1 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Lead sponsor of trials | 2016 to now |
| Compugen | Lead sponsor of trials | 2020 to now |